NanoVibronix

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. It targets wound healing and pain therapy, and can be administered at home, without the assistance of medical professionals. The firm's products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, Europe, India, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Elmsford, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Capital Market pursuant to an extension through December 15, 2020, to evidence

NanoVibronix Receives Positive Nasdaq Listing Determination

ELMSFORD, N.Y., Sept. 29, 2020 /PRNewswire/ -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announces its recent filing of a United States patent...

NanoVibronix Files U.S. Patent Application for PainShield® for Delivery of Cannabinoids for Alleviation of Chronic and Acute Pain

ELMSFORD, N.Y., Sept. 22, 2020 /PRNewswire/ -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced today that, due to...

NanoVibronix Increases Previously Announced Bought Deal to $1.8 Million

ELMSFORD, N.Y., Sept. 22, 2020 /PRNewswire/ -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced today that it has entered...

NanoVibronix Announces $1.5 Million Bought Deal Offering

NanoVibronix (NAOV) news for Tuesday includes approval from the U.S. Food and Drug Administration sending NAOV stock soaring.

NanoVibronix News: Why NAOV Stock Is Skyrocketing 104% Today

ELMSFORD, N.Y., Aug. 27, 2020 /PRNewswire/ -- NanoVibronix, Inc.

NanoVibronix Announces Closing of $3.4 Million Bought Deal Offering and Partial Exercise of Underwriter's Option to Purchase Additional Shares

ELMSFORD, N.Y., Aug. 24, 2020 /PRNewswire/ -- NanoVibronix, Inc.

NanoVibronix Increases Previously Announced Bought Deal to $3.25 Million

NanoVibronix Announces $2.5 Million Bought Deal Offering

NanoVibronix (NASDAQ: NAOV) shares are trading higher on Wednesday. The company announced it has received reimbursement approval from the U.S.

Why NanoVibronix's Stock Is Trading Higher Today

Enables Providers to Prescribe PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary Doctor Visits and Hospitalization During COVID-Related Stay-At-Home Proclamations Enables Providers to Prescribe PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary Doctor Visits and Hospitalization During COVID-Related Stay-At-Home Proclamations

NanoVibronix Receives Reimbursement Approval from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield™

Appealing to potential Regulatory agencies to increase use to reduce burden on the healthcare system Appealing to potential Regulatory agencies to increase use to reduce burden on the healthcare system

NanoVibronix looks to expand use of its UroShield Due to the potential to impact comorbidities related to COVID-19 Crisis

Nanocap medical device company NanoVibronix announced it's developing cannabidiol patches and cream utilizing a proprietary and nanoparticle-based infusion process.

NanoVibronix Announces Planned Launch Of CBD Patch, Cream

News for NanoVibronix Stock (NAOV)